drugset
drugset / Trial / NCT05594589

A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder

NCT05594589 ↗

Phase 2 Completed 65 enrolled Eisai Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of the study is to evaluate the treatment difference between lemborexant 5 milligram (mg) (LEM5) and placebo (PBO) on latency to persistent sleep (LPS) using polysomnography (PSG) on Day 30.

Timeline

Start
2022-11-30
Primary completion
2024-04-26
Completion
2024-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Lemborexant Small molecule 5 mg Oral
Subject Lemborexant Small molecule 10 mg Oral

Indications

sleep disorder, initiating and maintaining sleep